United States Nuclear Imaging Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

United States nuclear imaging market size in 2026 is estimated at USD 3.32 billion, growing from 2025 value of USD 3.20 billion with 2031 projections showing USD 4.02 billion, growing at 3.89% CAGR over 2026-2031. Growth arises from the convergence of precision positron emission tomography (PET), solid-state detector upgrades, and expanding theranostic pipelines that together improve clinical outcomes and economics for American providers. Separate Medicare payment for diagnostic radiopharmaceuticals priced above USD 630 removes a historic reimbursement hurdle and encourages nationwide adoption of high-value PET tracers^{[1]Source: Centers for Medicare & Medicaid Services, “Calendar Year 2025 Medicare Physician Fee Schedule Final Rule,” cms.gov} . FDA approvals of flurpiridaz F-18 for cardiac PET and novel prostate-specific membrane antigen (PSMA) agents accelerate the shift from single-photon emission computed tomography (SPECT) toward precision PET across hospitals and outpatient centers^{[2]Source: U.S. Food and Drug Administration, “FDA Approves Imaging Drug for Evaluation of Myocardial Ischemia and Infarction,” fda.gov} . Meanwhile, supply-chain disruptions following the October 2024 molybdenum-99 outage underscore the strategic value of domestic isotope manufacturing and automated dose-production systems. Competitive intensity heightens as equipment suppliers vertically integrate into radiopharmaceutical production, while distributors invest in alpha-emitting isotopes to serve expanding oncology pipelines.

Cardiovascular disease remains the leading cause of death in the United States, sustaining high procedure volumes for myocardial perfusion imaging across hospital networks. FDA clearance of flurpiridaz F-18 introduces an exercise-stress PET tracer with a 109-minute half-life that can be distributed regionally, broadening PET access beyond large academic centers. Medicare’s separate payment for high-cost tracers strengthens hospital economics, encouraging upgrades from SPECT to PET systems tailored for cardiology. Vendors promote ultra-low-dose protocols that lower radiation exposure, while AI segmentation tools automate perfusion quantification and shorten interpretation time. Together, these advances steer the United States nuclear imaging market toward value-based cardiac care models centered on diagnostic accuracy and cost efficiency.

Clinical evidence shows PET/CT delivers superior lesion detectability and quantitative accuracy, particularly in oncology staging, compared with legacy SPECT. The Biograph Trinion PET/CT launched in 2024 reduces energy consumption by 46% and incorporates AI-driven workflow tools that offset staffing shortages in busy imaging departments. Growing adoption of total-body PET platforms further boosts sensitivity and enables ultra-fast scans, however initial capital outlays remain large. Academic centers lead early uptake, creating a two-tier market where community hospitals retain SPECT for routine studies. Over time, reimbursement alignment and equipment life-cycle replacements are expected to migrate volumes to PET, elevating the United States nuclear imaging market.

As of 2025, Medicare pays separately for diagnostic radiopharmaceuticals costing more than USD 630, reversing prior bundled payment policies that discouraged hospital investment in innovative tracers. Commercial payers frequently mirror federal policy, broadening coverage across all 50 states. Blockbuster uptake of PSMA agents validates the new payment model; PYLARIFY surpassed USD 1 billion in 2024 US sales, showing strong provider demand once reimbursement hurdles lift. Companion diagnostics linked to radioligand therapies now benefit from aligned diagnostic and therapeutic payments, creating durable economic incentives and fueling expansion of the United States nuclear imaging market.

Cadmium-zinc-telluride (CZT) detectors deliver higher energy resolution than traditional sodium-iodide crystals, permitting 50% dose reduction without image degradation, as published in peer-reviewed US trials. These upgrades improve patient throughput and align with ALARA radiation guidelines. Siemens’ Symbia Evo and GE HealthCare’s latest SPECT cameras integrate self-calibration features that lessen technologist workload, crucial amid workforce shortages. Although acquisition costs remain premium, ROI improves in high-volume cardiac labs that can capitalize on rapid scan protocols.

A new PET/CT system can cost USD 225,000 – 750,000, excluding facility modifications, shielding, and tracer expenses that often exceed USD 1,000 per dose in complex oncology cases. Budget-constrained community hospitals struggle to justify such outlays when procedure volumes are modest. Leasing and mobile-service contracts provide interim access but may restrict scheduling flexibility and long-term economic efficiency. These factors slow the diffusion of hybrid imaging into low-density regions, tempering aggregate growth in the United States nuclear imaging market.

PET tracers such as fluorine-18 and gallium-68 decay rapidly, making imaging schedules sensitive to supply-chain disruptions. The October 2024 molybdenum-99 delay cut technetium supply by up to 100% for many US centers, forcing procedure cancellations and rescheduling. Federal funding for domestic reactors and cyclotrons aims to strengthen resilience; nonetheless, persistent logistics complexity hinders smaller sites lacking on-site production capabilities.